Sanofi is buying Vicebio, a biotech, that is developing vaccines for two viruses using the molecular clamp technology ...

A UK company developing technology spun out of the University of Queensland is poised for growth after being acquired by ...

“Vicebio’s Molecular Clamp technology introduces a purposefully simple but thoughtful approach to further improve vaccine ...

Breakthrough vaccine technology invented by the University of Queensland is at the centre of a landmark deal worth over $2bn struck by global pharmaceutical giant Sanofi.

Sanofi is paying up to US $1.6 billion for Vicebio, taking UQ’s Molecular Clamp vaccine tech global in Australia’s biggest university IP exit.

Sanofi is acquiring UK biotechnology company Vicebio for up to US$1.6 billion ($2.4 billion) in the largest deal involving a ...

It’s not a love-in yet and Hutchies boss Scott Hutchinson still reckons unions are “a pain in the ass” but relations are improving with just seven years to go before the opening ceremony of the 2032 ...

The US Securities and Exchange Commission has subpoenaed information from Telix, in relation to the company's therapeutic ...

Sanofi’s $1.76 billion acquisition of Vicebio delivers a windfall for the University of Queensland — and highlighted a ...

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...

Paris-based drugmaker Sanofi is acquiring U,K,-based Vicebio to gain its molecular clamp vaccine technology, with the total ...

French pharmaceutical and healthcare company Sanofi has agreed to buy the British biotechnology firm Vicebio for up to $1.6bn ...